Hong Kong and French researchers have assessedantibody responses to a panel of 15severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antigens, identifying and further validating antibodies to open reading frame (ORF)8 and ORF3b within the virus’s RNA as accurate serological markers of early and late SARS-CoV-2 infection.
Reducing the wait time for the hepatitis C virus (HCV) rapid antibody point-of-care test, from 20 minutes to 5 minutes, does not affect its sensitivity and is just as good for ruling out infection, according to a study.
Multisystem inflammatory syndrome (MIS) in critically ill children with the coronavirus disease 2019 (COVID-19) is more varied than previously thought, according to a new study. Despite this, complete recovery appears to be almost universal.
The use of tumour necrosis factor (TNF) antagonists does not lead to a worse prognosis in patients with coronavirus disease 2019 (COVID-19), according to a new study. Systemic corticosteroids, on the other hand, appear to be a significant risk factor for severe disease.
Achieving the World Health Organization’s (WHO) target to eliminate hepatitis C virus (HCV) by 2030 is possible in Singapore, but this requires immediate scaling up of treatment among injectable drug users (IDUs) together with harm reduction efforts, as suggested in a study.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.